Literature DB >> 18155812

Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease.

Pia S Pannaraj1, Joanna K Kelly, Marcia A Rench, Lawrence C Madoff, Morven S Edwards, Carol J Baker.   

Abstract

Alpha C protein, found in 76% of non-type III strains of group B Streptococcus (GBS), elicits antibodies protective against alpha C-expressing strains in experimental animals, making it an appealing carrier for a GBS conjugate vaccine. We determined whether natural exposure to alpha C elicits antibodies in women. Geometric mean concentrations of alpha C-specific IgM and IgG were similar by ELISA in sera from 58 alpha C GBS strain colonized and 174 age-matched non-colonized women (IgG 245 and 313 ng/ml; IgM 257 and 229 ng/ml, respectively), but acute sera from 13 women with invasive alpha C-expressing GBS infection had significantly higher concentrations (IgM 383 and IgG 476 ng/ml [p=0.036 and 0.038, respectively]). Convalescent sera from 5 of these women 16-49 days later had high alpha C-specific IgM and IgG concentrations (1355 and 4173 ng/ml, respectively). In vitro killing of alpha C-expressing GBS correlated with total alpha C-specific antibody concentration. Invasive disease but not colonization elicits alpha C-specific IgM and IgG in adults.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155812      PMCID: PMC2581930          DOI: 10.1016/j.vaccine.2007.11.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Antibodies to capsular polysaccharides of group B Streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate.

Authors:  H D Davies; C Adair; A McGeer; D Ma; S Robertson; M Mucenski; L Kowalsky; G Tyrell; C J Baker
Journal:  J Infect Dis       Date:  2001-06-26       Impact factor: 5.226

3.  Identification of a glycosaminoglycan binding region of the alpha C protein that mediates entry of group B Streptococci into host cells.

Authors:  Miriam J Baron; David J Filman; Gina A Prophete; James M Hogle; Lawrence C Madoff
Journal:  J Biol Chem       Date:  2007-01-26       Impact factor: 5.157

4.  Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes.

Authors:  C Gravekamp; D S Horensky; J L Michel; L C Madoff
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

5.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.

Authors:  S J Schrag; S Zywicki; M M Farley; A L Reingold; L H Harrison; L B Lefkowitz; J L Hadler; R Danila; P R Cieslak; A Schuchat
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

6.  Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus.

Authors:  M S Edwards; C J Baker; D L Kasper
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

7.  The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis.

Authors:  Anushua Sinha; Tracy A Lieu; Lawrence C Paoletti; Milton C Weinstein; Richard Platt
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

8.  Molecular characterization of nontypeable group B streptococcus.

Authors:  Srinivas V Ramaswamy; Patricia Ferrieri; Aurea E Flores; Lawrence C Paoletti
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

9.  Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha.

Authors:  C Larsson; M Stålhammar-Carlemalm; G Lindahl
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

10.  Alpha C protein of group B Streptococcus binds host cell surface glycosaminoglycan and enters cells by an actin-dependent mechanism.

Authors:  Miriam J Baron; Gilles R Bolduc; Marcia B Goldberg; Thierry C Aupérin; Lawrence C Madoff
Journal:  J Biol Chem       Date:  2004-03-23       Impact factor: 5.157

View more
  6 in total

1.  Structural vaccinology to thwart antigenic variation in microbial pathogens.

Authors:  Olaf Schneewind; Dominique Missiakas
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

2.  High-resolution crystal structure of Streptococcus agalactiae glyceraldehyde-3-phosphate dehydrogenase.

Authors:  Kang Zhou; Xiaojiao Fan; Yuelong Li; Caiying Zhang; Tengchuan Jin
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2018-03-23       Impact factor: 1.056

3.  Selection, recombination, and virulence gene diversity among group B streptococcal genotypes.

Authors:  A Cody Springman; David W Lacher; Guangxi Wu; Nicole Milton; Thomas S Whittam; H Dele Davies; Shannon D Manning
Journal:  J Bacteriol       Date:  2009-07-06       Impact factor: 3.490

Review 4.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

Review 5.  Interaction of Streptococcus agalactiae and Cellular Innate Immunity in Colonization and Disease.

Authors:  Sybille Landwehr-Kenzel; Philipp Henneke
Journal:  Front Immunol       Date:  2014-10-29       Impact factor: 7.561

6.  Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy.

Authors:  Sonwabile Dzanibe; Gaurav Kwatra; Peter V Adrian; Sheila Z Kimaro-Mlacha; Clare L Cutland; Shabir A Madhi
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.